Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOREM/NEO-1 neoadjuvant intratumoral ipilimumab + nivolumab for resectable melanoma
2025-522127-95-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in melanoma, cutaneous melanoma (CM) and mucosal melanoma (MM), sponsored by Unicancer. Primary endpoints: Pathological complete response or major pathologic response rate and Surgery delay due to treatment-related adverse events. Planned start Oct 2025; status: authorised.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanomacutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on 2025-522127-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522127-95-00.